He will join the company as CFO and an Executive Director on the board on 1 May 2017.
As previously announced, Richard will leave Consort after the half year results in December 2016. In the intervening period, Consort also announces the appointment of David Tilston as interim CFO to help effect a smooth transition with Paul when he joins on 1 May 2017.
Paul is an experienced finance director in multinational high technology manufacturing, consumer goods and retail businesses.
Paul has gained considerable experience during his 5 year tenure at The Vitec Group where he has built on his strong track record in operational management, delivering profitable growth and leading commercial, well-controlled finance functions.
Previously, Paul was Group Financial Controller at Signet Jewellers Limited between 2007 and 2011. Prior to that, he held a Senior Director role at RHM from 2004 to 2007, assisting with its flotation in 2005 and subsequent sale to Premier Foods.
Paul was with Smiths Group for more than ten years from 1993, including a number of divisional and operating company finance director roles. Paul is a Chartered Accountant having qualified with Ernst and Young and has a first class Masters degree in mechanical engineering, manufacture and management.
David joins the company having previously held a number of senior executive finance director roles, including Innovia Group, Mouchel Group, Findel, SABMiller and SThree.
Dr Peter Fellner, Chairman of Consort Medical, commented: “We look forward to welcoming Paul to Consort Medical. His strong track record in driving sustainable profitable growth in high technology manufacturing businesses will be a great asset to the company as we continue to reinforce our position as a leading provider of drug delivery solutions.”
Paul Hayes added: “I am delighted to be joining Consort Medical and help build on its leading position as a global contract development and manufacturing organisation. I look forward to working with the executive team and the board as the company continues to deliver strong organic growth from its robust and innovative product and pipeline portfolios.”